A Phase 2, Randomized, Single-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of Human Monoclonal Antibodies, BRII-196 and BRII-198, Administered by Intravenous Infusion for the Treatment of COVID-19 Patients
This study is to evaluate the safety, efficacy and pharmacokinetics profile of human monoclonal antibodies, BRII-196 and BRII-198 compared with placebo in patients with COVID-19.
100 项与 Brii Biosciences, Inc. 相关的临床结果
0 项与 Brii Biosciences, Inc. 相关的专利(医药)
100 项与 Brii Biosciences, Inc. 相关的药物交易
100 项与 Brii Biosciences, Inc. 相关的转化医学